Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors

Autor: C. Besse-Hayat, J. Bijon, Aude Ambresin, F. Spertini, D. Hohl, Christina Gianniou, E. Moret, S. Bogiatzi, Irmela Mantel
Rok vydání: 2021
Předmět:
Drug
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Bevacizumab
media_common.quotation_subject
Recombinant Fusion Proteins
Angiogenesis Inhibitors
Disease
Drug Hypersensitivity
Cellular and Molecular Neuroscience
Ranibizumab
Maculopapular rash
Medicine
Humans
media_common
Aflibercept
Retrospective Studies
Proteinuria
business.industry
Dermatology
Sensory Systems
Hypersensitivity reaction
Ophthalmology
Receptors
Vascular Endothelial Growth Factor
Intravitreal Injections
medicine.symptom
Angiogenesis Inhibitors/adverse effects
Bevacizumab/adverse effects
Drug Hypersensitivity/diagnosis
Drug Hypersensitivity/drug therapy
Drug Hypersensitivity/etiology
Ranibizumab/adverse effects
Cutaneous adverse events
Drug hypersensitivity reaction
Intravitreal anti-VEGF
business
medicine.drug
Zdroj: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, vol. 260, no. 3, pp. 1005-1014
ISSN: 1435-702X
Popis: Purpose To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs). Patients and methods Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept. Results Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. In two out of the six patients, reintroduction of either the same or an alternative anti-VEGF drug did induce a recurrence of the drug hypersensitivity reaction, while 4 patients showed no recurrence. Conclusion Cutaneous non-immediate drug hypersensitivity reactions secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease.
Databáze: OpenAIRE
Externí odkaz: